Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.

Slides:



Advertisements
Similar presentations
How to assess an abstract
Advertisements

How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
FAST STATS A 5-minute Review for the Evidence-Based Practitioner.
Understanding medical research
Reporting drugs and treatments Thomas Abraham JMSC 6090.
Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
Extension Article by Dr Tim Kenny
Should we??. Aspirin is useful! It is widely used in secondary prevention It reduces the yearly risk of vascular events by about a quarter This corresponds.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
 Mean: true average  Median: middle number once ranked  Mode: most repetitive  Range : difference between largest and smallest.
Multiple Choice Questions for discussion
EBD for Dental Staff Seminar 2: Core Critical Appraisal Dominic Hurst evidenced.qm.
Research Skills Basic understanding of P values and Confidence limits CHE Level 5 March 2014 Sian Moss.
Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.
Analyses of Covariance Comparing k means adjusting for 1 or more other variables (covariates) Ho: u 1 = u 2 = u 3 (Adjusting for X) Combines ANOVA and.
How to Analyze Therapy in the Medical Literature (part 2)
Understanding real research 4. Randomised controlled trials.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Evaluating Information and Presenting Risk Today’s Class Fact Sheet Assignment Review Evaluating Information Presenting Risk In-class Activity This week’s.
Quality Education for a Healthier Scotland Pharmacy Critical Appraisal Skills Basic I NHS Education Scotland Produced in collaboration with the Association.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Which Treatment ? For a patient, 64-year-old male For a patient, 64-year-old male No HT, DM, Heart failure, LV dysfunction No HT, DM, Heart failure, LV.
Template for writing medical news stories Thomas Abraham.
Biostatistics Case Studies 2005 Peter D. Christenson Biostatistician Session 6: “Number Needed to Treat” to Prevent One Case.
Statistics for the board September 14 th 2007 Jean-Sebastien Rachoin MD.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 10 Comparing Two Groups Section 10.1 Categorical Response: Comparing Two Proportions.
* Chapter 8 – we were estimating with confidence about a population * Chapter 9 – we were testing a claim about a population * Chapter 10 – we are comparing.
Compliance Original Study Design Randomised Surgical care Medical care.
Happy Finals Week Seniors! Today: 1.Time to get organized (10 min). 2.Small group presentations – Civic Participation Projects 3.Small Group Discussions.
Welcome and introduction William Tarnow-Mordi When printing handouts, please select ‘Notes Pages’ option in “Print what” menu in lower left area of Print.
4S: Scandinavian Simvastatin Survival Study
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
From EBM to SDM: Michel Labrecque MD PhD Michel Cauchon MD Department of Family and Emergency Medicine Université Laval Teaching how to apply evidence.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Article Title Resident Name, MD SVCH6/13/2016 Journal Club.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Objectives (Chapter 20) Comparing two proportions  Comparing 2 independent samples  Confidence interval for 2 proportion  Large sample method  Plus.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
20. Comparing two proportions
HelpDesk Answers Synthesizing the Evidence
The ALERT Trial.
Copyright © 2006 American Medical Association. All rights reserved.
CRITICAL NUMBERS LIVING WITH RISK
Confidence Intervals and p-values
Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.
Copyright © 2002 American Medical Association. All rights reserved.
EVIDENCE BASED MEDICINE
AIM HIGH Niacin plus Statin to prevent vascular events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
NAPLEX preparation: Biostatistics
مقدمه‌ای بر طب مبتنی بر شواهد
Baseline characteristics of HPS participants by prior diabetes
remember to round it to whole numbers
An activity-based journal club to help staff & students improve confidence at reading scientific papers Cornwall Health Library: Katy Oak Catriona Organ.
Interpreting Basic Statistics
THIS WEEK IN HEALTH… Wednesday – Test on Chapter One
LRC-CPPT and MRFIT Content Points:
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Figure 1 Relationships between magnitude of antithrombotic benefit vs
How to assess an abstract
Characteristics of included studies
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Basic statistics.
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Presentation transcript:

Reporting drugs and treatments Thomas Abraham

What we will learn today The difference between absolute and relative risk reduction A basic way to interpret P values and CI (confidence intervals) Number needed to treat (NNT) All of these are to help you evaluate and report on studies

Nov 1995, results of the trial of a drug announced 6,595 men in the west of Scotland with elevated cholesterol level participated in trial that lasted 5 years One group (treatment group ) was given a cholesterol lowering drug, pravastatin Another group (control group) was given a placebo

The results were impressive For those who took the drug: 31 % reduction of risk from heart attacks 28 % reduction of risk of death from coronary heart disease 31 % reduction of risk from heart attack, or death from heart disease

7.9% 5.5% Combined risk from heart attacks and death from heart disease

A 7.9% B 5.5% Control group Treatment group How do you measure the difference between these two groups? Risk from heart attack and death from heart disease

Absolute and relative risk reduction Absolute risk reduction looks at the difference between the treatments: A-B =2.4% Relative risk reduction looks at how much better one treatment is than the other (A-B/ A) x 100=30.37% A Control B Treatment 7.9% 5.5%

Absolute and relative risk Absolute risk is your risk of getting a particular disease, or condition Relative risk measures how much your risk is reduced with the new treatment, or procedure, compared with the old. Relative risk figures tend to look dramatic

Absolute risk reduction= Relative risk reduction=

A Control 6.5% B Treatm ent 4.6% Non fatal Myocardial Infarction Absolute Risk= ? Relative risk= ?

What were the different outcomes the study measured? Which outcome was the treatment the most effective in?

P values and Confidence Intervals ( CI) P value or probability value= The probability that a result could have occurred by chance P <.05 means a less than 5 percent probability that this result could have occurred by chance P<.01 means a less than 1 percent probability that this could have occurred by chance P <.001 means ? (move decimal point two places to the right)

According to scientific convention, P<.05 is significant, and P<.01 is highly significant.

Rank the following P values in terms of significance A. P<.1 B. P<.001 C. P<.01 D. P<.4 E. P<.04 F. P<.5 G. P<.0001 H. P<.05

Confidence intervals (CI) The confidence level tells you the range within which a true value will lie. It is generally measured at the 95% level. For example, 31 ( 17-43) 95% CI would indicate that 95% probability that the real value is between 17 and 43.

Number needed to Treat (NNT) The number of persons who needed to be treated with a drug, to prevent one person from getting the disease. Calculated as the inverse of the absolute risk reduction percentage

Absolute Risk Reduction = A-B=.5%. 5% means out of 100 people,.5 death was prevented To prevent one death: 200 people need to be treated ( 100/ARR%) Time-5 years. Therefore 200 people over 5 years to prevent 1 case

A Control 6.5% B Treatm ent 4.6% Non fatal Myocardial Infarction Absolute Risk Reduction = A-B= 2.9% Number needed to treat 100 people, 2.9 heart attacks prevented To prevent one heart attack= 100/ARR%= 100/2.9 Over 5 years

Check list When you hear about a new drug or treatment, check both absolute and relative risk reduction figures Ask ( or calculate) number needed to treat Ask about possible harms Ask about costs

5ekg&feature=related

From last week When evaluating research findings - Published or not published? - Quality of study: numbers of people or cases studied, methodology of study - Newsworthiness

Your course work Three news stories from journal articles Due Feb 28, March 28 and March 17(you can turn them in earlier if you wish) Length: words Go to Eureka alert, as well as Jama and BMJ Links to press releases on our course website Find an article that you think might be newsworthy and interesting.

Do some background research on the topic. Go to Pubmed for earlier studies Contact authors of paper, as well as people in Hong Kong who might have comments. Give yourself one week for each

Contacting paper authors Why? Not to “get a quote” To help bring out the significance, or importance of study To help you understand things you do not understand Read the paper and do research before getting in touch, so you do not ask basic questions

What I will look for Is the story newsworthy? Have you explained the research well? Have you looked at the costs and benefits (Look at the health news review website for an idea of what I will be looking for)